A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma

PLoS Genetics

Volumn 9, Issue 2, 2013, Pages

  Read, Renee D ^a,e   Fenton, Tim R ^b   Gomez, German G ^b   Wykosky, Jill ^b   Vandenberg, Scott R ^c   Babic, Ivan ^b   Iwanami, Akio ^d   Yang, Huijun ^b   Cavenee, Webster K ^b,c   Mischel, Paul S ^b,c   Furnari, Frank B ^b,c   Thomas, John B ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN RPL11; PROTEIN TYROSINE KINASE; RIO KINASE; RIO KINASE 1; RIO KINASE 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR PARAMETERS; CHEMOSENSITIVITY; COMPLEX FORMATION; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; ENZYME ACTIVITY; ENZYME REGULATION; GENETIC SCREENING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ORTHOLOGY; POSITIVE FEEDBACK; PROTEIN EXPRESSION; PROTEIN INDUCTION; RIBOSOMAL STRESS CHECKPOINT; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; ASTROCYTES; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DROSOPHILA MELANOGASTER; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, INSECT; GLIOBLASTOMA; HUMANS; MICE; MULTIPROTEIN COMPLEXES; NEUROGLIA; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84874773204     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003253     Document Type: Article

References (76)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710.
2. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, et al. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91: 7727-7731.
3. Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, et al. (2010) Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A 107: 2616-2621.
4. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, et al. (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25: 55-57.
5. Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, et al. (2009) Development of a novel mouse glioma model using lentiviral vectors. Nat Med 15: 110-116.
6. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, et al. (2002) Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1: 269-277.
7. Holland EC, Hively WP, DePinho RA, Varmus HE, (1998) A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12: 3675-3685.
8. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, et al. (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5: e8 doi:10.1371/journal.pmed.0050008.
9. Read RD, Cavenee WK, Furnari FB, Thomas JB, (2009) A Drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet 5: e1000374 doi:10.1371/journal.pgen.1000374.
10. Reiter LT, Bier E, (2002) Using Drosophila melanogaster to uncover human disease gene function and potential drug target proteins. Expert Opin Ther Targets 6: 387-399.
11. St Johnston D, (2002) The art and design of genetic screens: Drosophila melanogaster. Nat Rev Genet 3: 176-188.
12. Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, et al. (2007) A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448: 151-156.
13. Bellen HJ, Tong C, Tsuda H, (2011) 100 years of Drosophila research and its impact on vertebrate neuroscience: a history lesson for the future. Nat Rev Neurosci 11: 514-522.
14. Freeman MR, Doherty J, (2006) Glial cell biology in Drosophila and vertebrates. Trends Neurosci 29: 82-90.
15. LaRonde-LeBlanc N, Wlodawer A, (2005) A family portrait of the RIO kinases. J Biol Chem 280: 37297-37300.
16. Vanrobays E, Gelugne JP, Gleizes PE, Caizergues-Ferrer M, (2003) Late cytoplasmic maturation of the small ribosomal subunit requires RIO proteins in Saccharomyces cerevisiae. Mol Cell Biol 23: 2083-2095.
17. Widmann B, Wandrey F, Badertscher L, Wyler E, Pfannstiel J, et al. (2011) The kinase activity of human Rio1 is required for final steps of cytoplasmic maturation of 40S subunits. Mol Biol Cell.
18. Zemp I, Wild T, O'Donohue MF, Wandrey F, Widmann B, et al. (2009) Distinct cytoplasmic maturation steps of 40S ribosomal subunit precursors require hRio2. J Cell Biol 185: 1167-1180.
19. Baumas K, Soudet J, Caizergues-Ferrer M, Faubladier M, Henry Y, et al. (2012) Human RioK3 is a novel component of cytoplasmic pre-40S pre-ribosomal particles. RNA Biol 9: 162-174.
20. Strunk BS, Novak MN, Young CL, Karbstein K, (2012) A translation-like cycle is a quality control checkpoint for maturing 40S ribosome subunits. Cell 150: 111-121.
21. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127: 635-648.
22. Breitkreutz A, Choi H, Sharom JR, Boucher L, Neduva V, et al. (2010) A global protein kinase and phosphatase interaction network in yeast. Science 328: 1043-1046.
23. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848.
24. Manning G, Plowman GD, Hunter T, Sudarsanam S, (2002) Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci 27: 514-520.
25. Morrison DK, Murakami MS, Cleghon V, (2000) Protein kinases and phosphatases in the Drosophila genome. J Cell Biol 150: F57-62.
26. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, et al. (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39: D561-568.
27. Bjorklund M, Taipale M, Varjosalo M, Saharinen J, Lahdenpera J, et al. (2006) Identification of pathways regulating cell size and cell-cycle progression by RNAi. Nature 439: 1009-1013.
28. Bettencourt-Dias M, Giet R, Sinka R, Mazumdar A, Lock WG, et al. (2004) Genome-wide survey of protein kinases required for cell cycle progression. Nature 432: 980-987.
29. Friedman A, Perrimon N, (2006) A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling. Nature 444: 230-234.
30. Boutros M, Kiger AA, Armknecht S, Kerr K, Hild M, et al. (2004) Genome-wide RNAi analysis of growth and viability in Drosophila cells. Science 303: 832-835.
31. Neumuller RA, Richter C, Fischer A, Novatchkova M, Neumuller KG, et al. (2011) Genome-Wide Analysis of Self-Renewal in Drosophila Neural Stem Cells by Transgenic RNAi. Cell Stem Cell 8: 580-593.
32. Sousa-Nunes R, Yee LL, Gould AP, (2011) Fat cells reactivate quiescent neuroblasts via TOR and glial insulin relays in Drosophila. Nature 471: 508-512.
33. Reddy BV, Irvine KD, (2011) Regulation of Drosophila glial cell proliferation by Merlin-Hippo signaling. Development 138: 5201-5212.
34. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, et al. (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272: 2927-2935.
35. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, et al. (2009) Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 27: 980-987.
36. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, et al. (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4: 568-580.
37. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403.
38. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, et al. (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9: 469-479.
39. Ciesielski MJ, Fenstermaker RA, (2000) Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function. Oncogene 19: 810-820.
40. Gallia GL, Tyler BM, Hann CL, Siu IM, Giranda VL, et al. (2009) Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther 8: 386-393.
41. Pandita A, Aldape KD, Zadeh G, Guha A, James CD, (2004) Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Gene Chromosome Canc 39: 29-36.
42. Inda MD, Bonavia R, Mukasa A, Narita Y, Sah DW, et al. (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24: 1731-1745.
43. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, et al. (2012) Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 109: 3041-3046.
44. Chen AJ, Paik JH, Zhang H, Shukla SA, Mortensen R, et al. (2012) STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes Dev 26: 1459-1472.
45. Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, et al. (2010) Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A 107: 6912-6917.
46. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, et al. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11: 859-871.
47. Sunayama J, Sato A, Matsuda K, Tachibana K, Watanabe E, et al. (2011) FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells 29: 1327-1337.
48. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, et al. (2011) Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 1: 524-538.
49. Bashir T, Cloninger C, Artinian N, Anderson L, Bernath A, et al. (2012) Conditional astroglial rictor overexpression induces malignant glioma in mice. PLoS ONE 7: e47741 doi:10.1371/journal.pone.0047741.
50. Furnari FB, Lin H, Huang HS, Cavenee WK, (1997) Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A 94: 12479-12484.
51. Vanrobays E, Gleizes PE, Bousquet-Antonelli C, Noaillac-Depeyre J, Caizergues-Ferrer M, et al. (2001) Processing of 20S pre-rRNA to 18S ribosomal RNA in yeast requires Rrp10p, an essential non-ribosomal cytoplasmic protein. EMBO J 20: 4204-4213.
52. Fumagalli S, Thomas G, (2011) The role of p53 in ribosomopathies. Semin Hematol 48: 97-105.
53. Narla A, Ebert BL, (2010) Ribosomopathies: human disorders of ribosome dysfunction. Blood 115: 3196-3205.
54. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, et al. (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61: 1122-1128.
55. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, et al. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
56. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, et al. (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899.
57. Lowe SW, Ruley HE, Jacks T, Housman DE, (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
58. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
59. Villalonga-Planells R, Coll-Mulet L, Martinez-Soler F, Castano E, Acebes JJ, et al. (2011) Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS ONE 6: e18588 doi:10.1371/journal.pone.0018588.
60. Zinzalla V, Stracka D, Oppliger W, Hall MN, (2011) Activation of mTORC2 by association with the ribosome. Cell 144: 757-768.
61. Liu T, Deng M, Li J, Tong X, Wei Q, et al. (2011) Phosphorylation of right open reading frame 2 (Rio2) protein kinase by polo-like kinase 1 regulates mitotic progression. J Biol Chem 286: 36352-36360.
62. Marygold SJ, Roote J, Reuter G, Lambertsson A, Ashburner M, et al. (2007) The ribosomal protein genes and Minute loci of Drosophila melanogaster. Genome Biol 8: R216.
63. Macias E, Jin A, Deisenroth C, Bhat K, Mao H, et al. (2010) An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell 18: 231-243.
64. Burger K, Muhl B, Harasim T, Rohrmoser M, Malamoussi A, et al. (2010) Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem 285: 12416-12425.
65. Sun XX, Dai MS, Lu H, (2007) 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem 282: 8052-8059.
66. Goidts V, Bageritz J, Puccio L, Nakata S, Zapatka M, et al. (2012) RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene 31: 3235-3243.
67. Wurdak H, Zhu S, Romero A, Lorger M, Watson J, et al. (2010) An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 6: 37-47.
68. Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, et al. (2010) Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A 107: 11501-11506.
69. Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, et al. (2011) Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro Oncol 13: 367-375.
70. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024.
71. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, et al. (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8: 1725-1738.
72. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, et al. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9: 1956-1967.
73. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, et al. (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28: 1248-1250.
74. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J, (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 105: 17414-17419.
75. Obenauer JC, Cantley LC, Yaffe MB, (2003) Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31: 3635-3641.
76. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, et al. (2011) PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 40: D261-270.